Generics Enter the Market
The market for weight loss medications in India is poised for a dramatic shift following the patent expiry of a key drug. This has paved the way for domestic
manufacturers to introduce generic versions, leading to unprecedented price reductions of 70% to 90%. This development is particularly significant as it brings once prohibitively expensive treatments within reach of a much broader segment of the population. Previously, the high cost of originator brands acted as a substantial barrier for many individuals struggling with obesity and related health concerns. Now, with generics hitting the shelves, the monthly cost for these GLP-1 receptor agonists could drop to as low as Rs 1,290, a stark contrast to the previous thousands of rupees patients had to bear. This move is expected to democratize access to effective weight management therapies, potentially impacting public health positively by addressing the growing epidemic of obesity and its associated chronic diseases.
Key Players & Pricing
Several domestic pharmaceutical companies are leading the charge in making these life-changing generic weight loss drugs accessible. Natco Pharmaceuticals and Eris Lifesciences are among the first to launch their versions, offering the lowest dose at Rs 1,290 per month. Natco plans to market its products, 'Semanat' and 'Semafull,' in various dosages including 2 mg, 4 mg, and 8 mg. The multi-dose vials will range from Rs 1,290 for the lowest dosage to Rs 1,750 for the highest. Additionally, Natco will introduce an easy-to-inject pen device next month, priced between Rs 4,000 and Rs 4,500 depending on the dose. Eris Lifesciences is also launching its product, 'Sundae,' at comparable price points to Natco's offerings, having recently formed a strategic partnership with Natco for semaglutide commercialization in India. These injectables are scheduled to be available from Saturday, marking a significant competitive move against the originator brands whose monthly costs typically range from Rs 8,800 to Rs 16,400.
Market Impact & Projections
The advent of affordable generic semaglutide is anticipated to significantly boost the sales of GLP-1 units in India, with analysts projecting a two-fold increase within the next three months. The current monthly sales of these drugs hover around 1.2 lakh units, a figure expected to double as consumption rises due to the steep price cuts. This increased affordability is particularly crucial for managing chronic conditions like obesity, where long-term medication adherence is vital. Sheetal Sapale, vice-president (commercial) at Pharmarack, notes that the improved accessibility of semaglutide will likely shift new patient onboarding for obesity treatment towards this more affordable option. The Indian GLP-1 market, which was valued at approximately Rs 1,500 crore as of February, has been predominantly led by Eli Lilly's Mounjaro and Novo Nordisk's Wegovy and Ozempic. With generics now entering the fray, a more competitive pricing structure is expected, potentially leading to further innovation and expanded treatment options for patients.
Natco's First Mover Advantage
Natco Pharmaceuticals is making a significant impact as a first mover in the generic semaglutide market in India. The company has secured approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic semaglutide in both multi-dose vials and pen devices. Natco's vial offerings are reportedly up to 90% cheaper than the innovator product, while their pre-filled pens, designed for full monthly doses, will be priced up to 72% lower. A key advantage of Natco's vial dosage form is its potential for customized dosing, allowing patients better control over their treatment and potentially improving cost management. Unlike the originator's weekly pre-filled syringe format, which contains four doses, Natco's approach aims to enhance patient accessibility and promote long-term compliance with GLP-1 therapy. This strategic move by Natco is expected to broaden the reach of these important medications.
